Burning Rock Biotech Ltd (BNR) stock
Close on Nov 13, 2026Market cap $144.67MP/E –Yield –
Burning Rock Biotech Ltd grew revenue 4.6% to CN¥539.57M over fiscal 2025. Free cash flow was -CN¥33.69M. At the latest close the market valued the company at CN¥965.83M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- CN¥965.83M
- P/E ratio
- –
- Price to sales
- 1.79
- Price to book
- 1.80
- Dividend yield
- –
- Free cash flow yield
- -3.49%
Fundamentals
- Revenue
- CN¥539.57M
- Net income
- -CN¥55.35M
- Free cash flow
- -CN¥33.69M
Trading
- Previous close
- $13.33
- Open
- $13.29
- Day's range
- $13.29 – $13.29
- Volume
- 463
- Average volume (20 days)
- 24,799
- Beta (5 years)
- 1.74
- RSI (14 days)
- 52.1
- Volatility (1 year)
- 127.9%
- Relative volume
- 0.02×
- WACC
- 13.8%
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BNR | S&P 500 | Difference | BNR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.4% | -3.0% | −8.4 pts | ||
| 3 months | +43.1% | -2.8% | +45.8 pts | ||
| Year to date | -34.0% | +11.5% | −45.5 pts | ||
| 1 year | +17.4% | +13.5% | +3.9 pts | ||
| 3 years | +38.7% | +77.7% | −39.0 pts | +11.5% | +21.1% |
| 5 years | -90.9% | +72.6% | −163.5 pts | -38.1% | +11.5% |
Nine years at a glance
Fiscal years 2017 to 2025, CNY
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Burning Rock Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Burning Rock Biotech
Services-Medical Laboratories
Burning Rock Biotech develops and provides next-generation sequencing diagnostic solutions for cancer therapy selection, minimal residual disease monitoring, and early cancer detection. Its offerings include tissue and liquid biopsy testing panels, such as OncoScreen and OncoCompass, automated library preparation systems, and diagnostic reagent kits covering multiple solid tumor types like lung, colorectal, and breast cancers. The company serves oncologists, healthcare facilities, cancer patients, and pharmaceutical companies, supporting clinical trials through central laboratory testing and companion diagnostics development.
Company profile, executives and historyBurning Rock Biotech stock: common questions
What is Burning Rock Biotech's stock price?
BNR closed at $13.29 on Nov 13, 2026, down 0.30% on the day.
What is Burning Rock Biotech's market cap?
Burning Rock Biotech was worth $144.67M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
How much revenue does Burning Rock Biotech make?
Burning Rock Biotech reported revenue of CN¥539.57M for fiscal 2025, up 4.6% from a year earlier.
Does Burning Rock Biotech pay a dividend?
No. Burning Rock Biotech has not paid a cash dividend over the last twelve months.
How has BNR stock performed over the past year?
Including dividends, BNR returned +17.4% over the past year, against +13.5% for the S&P 500.
Who are Burning Rock Biotech's competitors?
Companies most similar to Burning Rock Biotech by business, industry and size include VCYT, GH, CAI, FLGT, BLLN.
See a number that looks wrong?